- Home
- EDSA vs MBIO Comparison
EDSA vs MBIO Comparison
Compare EDSA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDSA | MBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Canada | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 6.2M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | EDSA | MBIO |
|---|---|---|
| Price | $7.04 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 7.7M | 32.6K |
| Earning Date | 05-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.53 |
| 52 Week High | $9.37 | $7.00 |
Technical Indicators
Market Signals| Indicator | EDSA | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 37.58 |
| Support Level | $1.69 | $0.53 |
| Resistance Level | $8.74 | $1.00 |
| Average True Range (ATR) | 1.48 | 0.06 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 59.79 | 22.22 |
Price Performance
Historical ComparisonAbout EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.